Dr. Mario Saltarelli, Director of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an effective treatment methodology for such neurological disorders as Alzheimer’s disease, Lewy Body Dementia and Parkinson’s. In short, Bioasis’ final frontier solution could very well revolutionize medical science, potentially helping to heal the one billion people suffering from neurological disorders worldwide. Tune in!
Bioasis Technologies (BTI.V): First Glance With Jody Vance (Ep 62)
Latest Articles
- Standard Uranium (STND.V) signs LOI to option out the Rocas project, and remains the operator
- Cleghorn Minerals Ltd.: Navigating the Metals Market Landscape
- Lithium Ionic (LTH.C): Walking a well-trodden path in Brazil’s big lithium region
- Skyharbour Resources (SYH.V) & Trident Resources (ROCK.V): Turbo charged on near term potential
- Abasca Resources: Navigating Uranium and Graphite Markets in 2025
Top Searches
Abitibi Greenstone Belt Barrick Gold best canadian cannabis company biotech Bitcoin blockchain bullion Canada cannabis CBD China Chris Parry covid cryptocurrency DEFN.V Fraser Institute gambling Gold gold price. gold prices Greg Nolan hemp inflation interest rates investing investments lithium Lukas Kane marijuana mining money Newmont Goldcorp Nexus Gold pharmaceuticals psychedelics resources silver stock market stocks technology trading uranium wealth wealth creation weed
by
Leave a Reply